Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration

Oszajca, Katarzyna; Szemraj, Maciej; Szemraj, Janusz; Jurowski, Piotr

doi:10.1080/13816810.2018.1525752

Cited by 6 publications

(15 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes the polymorphisms of MMP genes that have been analyzed in AMD patients. Polymorphisms in MMP-1 (rs1799756) [30], MMP-3 (rs3025058) [26,32], and MMP-7 (rs11568818) [30,31] genes showed no statistical association with either the risk of AMD or disease progression.…”

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 89%

“…Fiotti et al [24] associated exudative AMD with longer microsatelites in the gene promoter region. The rs142450006, rs3918241, and rs3918242 MMP-9 polymorphisms were associated with an increased risk of AMD [27,28,31,32]. The rs142450006 MMP-9 polymorphism was also associated with progression to choroidal neovascularization [27,28].…”

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 98%

“…Four polymorphisms of the MMP-2 gene were analyzed: rs243866, rs243865, rs2287074, and rs2285053 (Table 1) [29,[31][32][33][34][35][36][37]. The rs243866 and rs2285053 MMP-2 genetic variants were not associated with AMD [29,31,32]. Seitzman et al [37] noted that the A allele of MMP-2 rs2287074 polymorphism was associated with a decreased risk of AMD.…”

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 99%

“…The rs10895322 polymorphism is A>G intron variant due to the fact that it can alter the gene expression and therefore modify the neovascular lesion size in neovascular AMD [38]. Finally, four genetic variants of MMP-9 gene were analyzed (Table 1) [24,27,28,31,32]. Fiotti et al [24] associated exudative AMD with longer microsatelites in the gene promoter region.…”

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 99%

See 3 more Smart Citations

Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD)

García-Onrubia

Valentín-Bravo

Coco‐Martín

et al. 2020

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a complex, multifactorial and progressive retinal disease affecting millions of people worldwide. In developed countries, it is the leading cause of vision loss and legal blindness among the elderly. Although the pathogenesis of AMD is still barely understood, recent studies have reported that disorders in the regulation of the extracellular matrix (ECM) play an important role in its etiopathogenesis. The dynamic metabolism of the ECM is closely regulated by matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs). The present review focuses on the crucial processes that occur at the level of the Bruch’s membrane, with special emphasis on MMPs, TIMPs, and the polymorphisms associated with increased susceptibility to AMD development. A systematic literature search was performed, covering the years 1990–2020, using the following keywords: AMD, extracellular matrix, Bruch’s membrane, MMPs, TIMPs, and MMPs polymorphisms in AMD. In both early and advanced AMD, the pathological dynamic changes of ECM structural components are caused by the dysfunction of specific regulators and by the influence of other regulatory systems connected with both genetic and environmental factors. Better insight into the pathological role of MMP/TIMP complexes may lead to the development of new strategies for AMD treatment and prevention.

show abstract

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 89%

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 98%

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 99%

Section: Matrix Metalloproteinases and Tissue Inhibitors Of Metalloprmentioning

confidence: 99%

See 2 more Smart Citations

Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD)

García-Onrubia

Valentín-Bravo

Coco‐Martín

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Using online search databases with keywords including "polymorphism", "age-related macular degeneration", and "meta-analysis", I summarized the findings from the latest published meta-analysis [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] as shown in Figure 1. Moreover, in this short communication additional meta-analysis of TNFα, CCL-2, MMP3, MMP7, MMP9, and TIMP2 were also included [19][20][21][22][23][24][25][26][27][28][29] . It was shown that a protective effect of TNFα -863A carrier (A vs C, OR = 0.67, P = 0.007; AA+CA vs CC, OR = 0.58, P = 0.001; CA vs AA+CC, OR = 0.55, P = 0.001; and CA vs CC, OR = 0.54, P = 0.001, Figure 2A-D) and TIMP2 -418C carrier (GC vs CC+GG, OR = 0.54, P = 0.018; and GC vs GG, OR = 0.56, P = 0.046, Figure 2E,F) to the development of AMD.…”

mentioning

confidence: 99%